Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Titel:
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Auteur:
Kater, Arnon P. Kersting, Sabina van Norden, Yvette Dubois, Julie Dobber, Johan A. Mellink, Clemens H. Evers, Ludo M. Croon-de Boer, Fransien Schreurs, John van der Spek, Ellen Visser, Hein Idink, Cecile Wittebol, Shulamiet Hoogendoorn, Mels Tonino, Sanne H. Mobasher, Mehrdad Levin, Mark-David